SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Vascular Biogenics Ltd. (VBLT)

VBLT RSS Feed
Add VBLT Price Alert      Hide Sticky   Hide Intro
Moderator: gr8db8
Search This Board: 
Last Post: 10/22/2017 12:00:55 AM - Followers: 41 - Board type: Free - Posts Today: 1

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. As of June 6, 2014, it has developed two programs based on these platforms an oncology program and an anti-inflammatory program. Its lead product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. The Company has also received orphan drug designation in both the United States and Europe. The Company’s oncology program is based on its Vascular Targeting System (VTS), platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. http://www.vblrx.com
SureTrader
Interactive Brokers Advertisement
VBLT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VBLT News: Report of Foreign Issuer (6-k) 10/20/2017 09:01:57 AM
VBLT News: Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) 10/11/2017 04:32:10 PM
VBLT News: VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in... 10/02/2017 07:00:00 AM
VBLT News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/18/2017 05:15:09 PM
VBLT News: Report of Foreign Issuer (6-k) 09/13/2017 04:32:33 PM
PostSubject
#1530   I consider vb111 a vaccine and not a Oren1976 10/22/17 12:00:54 AM
#1529   I agree, the drug holds promise and this staccani 10/21/17 02:34:44 PM
#1528   "The sponsor has provided preliminary clinical data that gr8db8 10/21/17 01:03:26 PM
#1527   My take away is that a medical committee gr8db8 10/21/17 12:50:24 PM
#1526   I think it is a Nice vote of staccani 10/21/17 12:23:05 PM
#1525   Thanks for posting Your thoughts re EMA designation mjw007 10/21/17 08:07:30 AM
#1524   '...The COMP considered that the response analysis and staccani 10/21/17 02:11:17 AM
#1523   Ovarian orphan news came out last week, if gr8db8 10/20/17 08:59:12 PM
#1522   I second that Staccani ! Nice news out this mjw007 10/20/17 07:54:12 AM
#1521   I wish VB 111 will have same luck staccani 10/19/17 10:15:15 AM
#1520   I will give u an example of how Oren1976 10/19/17 08:29:31 AM
#1519   Gbm is highly highly vasculature metastases are also Oren1976 10/19/17 08:25:31 AM
#1518   https://en.m.wikipedia.org/wiki/Bevacizumab. This is just tip of Oren1976 10/19/17 07:50:48 AM
#1517   I will be clearer avastin doesn't extend over Oren1976 10/19/17 07:47:24 AM
#1516   My point is that avastin is not an Oren1976 10/19/17 07:41:31 AM
#1515   Remember DNDN when it redid the trial under Jumpinjackas 10/19/17 01:05:21 AM
#1514   How did they double the MOS without removing Jumpinjackas 10/19/17 01:03:36 AM
#1513   Oren, not sure what is your point. Avastin staccani 10/19/17 01:03:21 AM
#1512   You can say everything is nonsense since nothing gr8db8 10/19/17 12:16:39 AM
#1511   pro's and con's of SPA. It seems like gr8db8 10/18/17 11:41:25 PM
#1510   Phase success and LOA for drugs receiving a gr8db8 10/18/17 11:28:22 PM
#1509   Another proof the antiangiogenesis is nonsense - look Oren1976 10/18/17 02:19:19 PM
#1508   https://soundcloud.com/levine-media-group/vbl-targets-brain-and-other-cancers-wi Oren1976 10/18/17 02:05:40 PM
#1507   I can't tell but the company can tell Oren1976 10/18/17 01:58:47 PM
#1506   Oren, you cannot tell if the two drugs staccani 10/18/17 11:05:07 AM
#1505   Thank you for replying. Extremist223 10/16/17 05:11:13 PM
#1504   extremist .. here is a good place to gr8db8 10/16/17 04:59:48 PM
#1503   Hi, I'm new here. Can anyone explain how Extremist223 10/15/17 08:07:14 PM
#1502   http://www.mdpi.com/2227-9059/5/1/8/pdf Oncolytic Vesicular Stomatitis Virus as Jumpinjackas 10/15/17 04:09:27 PM
#1501   U can compare it to an airplane with Oren1976 10/14/17 07:30:42 PM
#1500   Correction "By doing that's I referred to the Oren1976 10/14/17 07:24:56 PM
#1499   Ph2 started vb111 only and then when progression Oren1976 10/14/17 07:23:38 PM
#1498   Why? Why do you think it will be Jumpinjackas 10/14/17 03:29:06 PM
#1497   Worst case is what u described as 2nd Oren1976 10/14/17 11:57:03 AM
#1496   Oren, please re-read gr8's comment. If Ph2 VB111 showed: wcopeland 10/14/17 11:17:13 AM
#1495   Having more long term survivors in combo is Oren1976 10/13/17 11:42:40 PM
#1494   Oren ... the way I understand mOS and gr8db8 10/13/17 05:10:45 PM
#1493   Ok = lower than ph2 extraordinary = same Oren1976 10/13/17 03:45:19 PM
#1492   We are not talking about avg -vs- median. Jumpinjackas 10/13/17 03:12:01 PM
#1491   U make it complicated . Let's say there Oren1976 10/13/17 03:01:41 PM
#1490   I'm starting to think that you do need Jumpinjackas 10/13/17 02:52:56 PM
#1489   Of course median can be low and 12 Oren1976 10/13/17 02:42:30 PM
#1488   He ignored my question on the same. I Jumpinjackas 10/13/17 11:57:56 AM
#1487   Can you explain how mOS will just be gr8db8 10/13/17 11:19:35 AM
#1486   There you go again. MOS is the primary Jumpinjackas 10/13/17 08:13:29 AM
#1485   Haha read my lips they already met the Oren1976 10/13/17 07:07:10 AM
#1484   If they don't pass phase III then no Jumpinjackas 10/13/17 06:52:48 AM
#1483   Forget all u heard so far about vb-111. Oren1976 10/13/17 02:47:57 AM
#1482   My memory tells me but can't recall where Oren1976 10/12/17 08:13:38 PM
#1481   My take on this is that the FDA gr8db8 10/12/17 06:45:12 PM
PostSubject